TABLE 1.
Baseline characteristics of patients with stable fibrosing interstitial lung disease (ILD)
| Patients | Healthy controls | |
| Subjects, n | 119 | 38 |
| Age years | 70±9 | 52±11 |
| Sex (male), n (%) | 69 (58) | 16 (42) |
| Smoking history (yes), n (%) | 73 (61) | 11 (29) |
| Diagnosis of fibrosing ILD, n | ||
| IPF | 78 | |
| NSIP | 11 | |
| Unclassifiable ILD | 10 | |
| PPFE | 8 | |
| CTD-ILD | 12 | |
| Treatment at the time of analysis, n | ||
| Corticosteroids | 25 | |
| Pirfenidone | 19 | |
| Nintedanib | 15 | |
| Laboratory data | ||
| LDH U· L−1 | 252±54 | |
| KL-6 U m·L−1 | 1029±680 | |
| SP-D ng· mL−1 | 215±148 | |
| Pulmonary function | ||
| FVC mL | 2133±743 | |
| %FVC | 75.9±20.4 | |
| DLCO % | 59.8±20.9 | |
Data are presented as mean±sd, unless otherwise stated. IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial pneumonia; CTD-ILD: connective tissue disease-associated ILD; PPFE: pleuroparenchymal fibroelastosis; LDH: lactate dehydrogenase; SP-D: surfactant protein-D; KL-6: Krebs von den Lungen-6; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.